{
    "nct_id": "NCT04535544",
    "official_title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus",
    "inclusion_criteria": "* Medically stable based on physical examination, medical history, vital signs, electrocardiogram (ECG) at screening\n* Chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) co-infection with documentation at least 6 months prior to screening\n* For Part 1: hepatitis D RNA (HDV RNA) greater than or equal to (>=) 1000 international units per milliliter (IU/mL) at screening. For Part 2: must have HDV RNA values >= 500 IU/mL, and must have hepatitis B surface antigen (HBsAg) values less than or equal to (<=) 10000 IU/mL at screening or HDV RNA values at screening are <= 100000 IU/mL\n* Alanine aminotransferase (ALT) greater than upper limit normal (ULN) but less than 10 times (ULN)\n* Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m^2), extremes included\n* Highly effective contraceptive measures in place for female participants of childbearing potential or male participants with female partners of childbearing potential\n* Non-cirrhotic participants and participants with compensated cirrhosis (Child Pugh class A) at screening (Part 1) and participants must have absence of cirrhosis and platelet count of >= 140000 per deciliter (dL) for enrollment into Part-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Evidence of infection with hepatitis A, C, or E virus infection or evidence of human immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening\n* History or evidence of clinical signs/symptoms of hepatic decompensation including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices or any laboratory abnormalities indicating a reduced liver function as defined in the protocol\n* Evidence of liver disease of non-HBV/HDV etiology\n* Signs of hepatocellular carcinoma (HCC)\n* Significant laboratory abnormalities as defined in the protocol at screening\n* Participants with a history of malignancy within 5 years before screening\n* Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol\n* History of or current cardiac arrhythmia or history or clinical evidence of significant or unstable cardiac disease\n* Participants with any current or previous illness for which, in the opinion of the investigator and/or sponsor, participation would not be in the best interest of the participant\n* History of or current clinically significant skin disease or drug rash\n* Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 or its excipients or excipients of the placebo content\n* Contraindications to the use of entecavir (ETV), tenofovir disoproxil, or tenofovir alafenamide (TAF) per local prescribing information\n* Participants who have taken any therapies disallowed per protocol\n* Female participants who are pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study intervention\n* Male participants who plan to father a child while enrolled\n* Participants who had or planned major surgery, (example, requiring general anesthesia) or who have received an organ transplant\n* Vulnerable participants (example, incarcerated individuals, individuals under a legal protection measure)",
    "miscellaneous_criteria": ""
}